The five discovered genes (DUSP22, MAPK14, MAPKAPK3, STAT1, and VCP) have the potential to further improve the current biomarkers developed for RCC (reviewed in [61]), and can be analyzed using biopsies obtained from normal, readily assessed tissues, such as bone marrow. This evidence concerns the gene MAPKAPK3 and renal cell adenocarcinoma.